Zhu L. · Dong C. · Yue X. · Ge P. · Zheng G. · Ye Z. · Pan B.

Author affiliations

Hebei General Hospital, Shijiazhuang, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: December 03, 2021
Accepted: April 05, 2022
Published online: May 24, 2022

Number of Print Pages: 11
Number of Figures: 6
Number of Tables: 0

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Abstract

Background: Neuroinflammation subsequent to traumatic brain injury (TBI) is important for the recovery of patients and is associated with neurodegenerative changes post-TBI. The tripartite motif containing 44 (TRIM44) protein is an E3 ligase involved in the regulation of immune function with no previously known link to TBI. This study explores the connection between TRIM44 and TBI. Methods: After induction of TBI in rats by control cortex injury, TRIM44 expressions were determined with quantitative real-time reverse transcription polymerase chain reaction and Western blot, and Toll-like receptor 4 (TLR4)-NF-κB signaling was examined by the expression of TLR4, p65 phosphorylation, and the specific NF-κB transcription activity. The effects of TRIM44 knockdown on inflammation, neurological function, and TLR4-NF-κB signaling in TBI rats were revealed by the detection of proinflammatory cytokines and TLR4-NF-κB signaling molecules, modified neurological severity score, brain water content, and Evans blue permeability. Results: We found that TRIM44 expression was significantly increased following TBI induction along with TLR4-NF-κB activation. Silencing of TRIM44 suppressed proinflammatory cytokine production, improved neurological outcomes, alleviated brain edema, and inhibited TLR4-NF-κB signaling in TBI rats. Conclusion: Our findings suggest that suppressing TRIM44 or modulation of relevant pathways may be a therapeutic strategy for TBI.

© 2022 S. Karger AG, Basel

References Fazel S, Wolf A, Pillas D, Lichtenstein P, Långström N. Suicide, fatal injuries, and other causes of premature mortality in patients with traumatic brain injury: a 41-year Swedish population study. JAMA Psychiatry. 2014;71:326–33. Bagnato S, Boccagni C. Moderate/severe traumatic brain injury as a trigger of chronic neurodegeneration in humans. Neural Regen Res. 2020;15:1247–8. Wang HC, Sun CF, Chen H, Chen MS, Shen G, Ma YB, et al. Where are we in the modelling of traumatic brain injury? Models complicated by secondary brain insults. Brain Inj. 2014;28:1491–503. Hinson HE, Rowell S, Schreiber M. Clinical evidence of inflammation driving secondary brain injury: a systematic review. J Trauma Acute Care Surg. 2015;78:184–91. Sun Z, Nyanzu M, Yang S, Zhu X, Wang K, Ru J, et al. VX765 attenuates pyroptosis and HMGB1/TLR4/NF-κB pathways to improve functional outcomes in TBI mice. Oxid Med Cell Longev. 2020;2020:7879629. Tang H, Hua F, Wang J, Yousuf S, Atif F, Sayeed I, et al. Progesterone and vitamin D combination therapy modulates inflammatory response after traumatic brain injury. Brain Inj. 2015;29:1165–74. Feng Y, Cui C, Liu X, Wu Q, Hu F, Zhang H, et al. Protective role of apocynin via suppression of neuronal autophagy and TLR4/NF-κB signaling pathway in a rat model of traumatic brain injury. Neurochem Res. 2017;42:3296–309. Zhang D, Li H, Li T, Zhou M, Hao S, Yan H, et al. Tlr4 inhibitor resatorvid provides neuroprotection in experimental traumatic brain injury: implication in the treatment of human brain injury. Neurochem Int. 2014;75:11–8. Ahmad A, Crupi R, Campolo M, Genovese T, Esposito E, Cuzzocrea S. Absence of tlr4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice. PLoS One. 2013;8:e57208. Yao X, Liu S, Ding W, Yue P, Jiang Q, Zhao M, et al. Tlr4 signal ablation attenuated neurological deficits by regulating microglial m1/m2 phenotype after traumatic brain injury in mice. J Neuroimmunol. 2017;310:38–45. Jiang H, Wang Y, Liang X, Xing X, Xu X, Zhou C. Toll-like receptor 4 knockdown attenuates brain damage and neuroinflammation after traumatic brain injury via inhibiting neuronal autophagy and astrocyte activation. Cell Mol Neurobiol. 2018;38(5):1009–19. Yang B, Wang J, Wang Y, Zhou H, Wu X, Tian Z, et al. Novel function of trim44 promotes an antiviral response by stabilizing visa. J Immunol. 2013;190:3613–9. Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T, et al. TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-κB signaling. Int J Mol Sci. 2017;18(9):1931. Luo Q, Lin H, Ye X, Huang J, Lu S, Xu L. Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway. Int J Clin Oncol. 2015;20:508–17. Wu J, He J, Tian X, Luo Y, Zhong J, Zhang H, et al. Microrna-9-5p alleviates blood-brain barrier damage and neuroinflammation after traumatic brain injury. J Neurochem. 2020;153:710–26. Aida V, Niedzielko TL, Szaflarski JP, Floyd CL. Acute administration of perampanel, an ampa receptor antagonist, reduces cognitive impairments after traumatic brain injury in rats. Exp Neurol. 2020;327:113222. Yang P, Manaenko A, Xu F, Miao L, Wang G, Hu X, et al. Role of PDGF-D and PDGFR-β in neuroinflammation in experimental ICH mice model. Exp Neurol. 2016;283:157–64. Wei CY, Wang L, Zhu MX, Deng XY, Wang DH, Zhang SM, et al. Trim44 activates the akt/mtor signal pathway to induce melanoma progression by stabilizing tlr4. J Exp Clin Cancer Res. 2019;38:137. Cruz-Haces M, Tang J, Acosta G, Fernandez J, Shi R. Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Transl Neurodegener. 2017;6:20. Kempuraj D, Ahmed ME, Selvakumar GP, Thangavel R, Raikwar SP, Zaheer SA, et al. Acute traumatic brain injury-induced neuroinflammatory response and neurovascular disorders in the brain. Neurotox Res. 2021 Apr;39(2):359–68. Simon DW, McGeachy MJ, Bayır H, Clark RS, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13:171–91. Wang Y, Ge P, Zhu Y. Tlr2 and tlr4 in the brain injury caused by cerebral ischemia and reperfusion. Mediators Inflamm. 2013;2013:124614. Tang R, Lin YM, Liu HX, Wang ES. Neuroprotective effect of docosahexaenoic acid in rat traumatic brain injury model via regulation of tlr4/nf-kappa b signaling pathway. Int J Biochem Cell Biol. 2018;99:64–71. Yamada Y, Kimura N, Takayama KI, Sato Y, Suzuki T, Azuma K, et al. Trim44 promotes cell proliferation and migration by inhibiting frk in renal cell carcinoma. Cancer Sci. 2020;111:881–90. Xiao G, Yang Q, Bao Z, Mao H, Zhang Y, Lin S. Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies: a meta-analysis. BMC Cancer. 2020;20:525. Yamada Y, Takayama KI, Fujimura T, Ashikari D, Obinata D, Takahashi S, et al. A novel prognostic factor trim44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Sci. 2017;108:32–41. Zhou Z, Liu Y, Ma M, Chang L. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway. Biomed Pharmacother. 2017;96:98–103. Wu Y, Wu H, Guo X, Pluimer B, Zhao Z. Blood-brain barrier dysfunction in mild traumatic brain injury: evidence from preclinical murine models. Front Physiol. 2020;11:1030. Sebastiani A, Hirnet T, Jahn-Eimermacher A, Thal SC. Comparison of speed-vacuum method and heat-drying method to measure brain water content of small brain samples. J Neurosci Methods. 2017;276:73–8. Article / Publication Details

First-Page Preview

Received: December 03, 2021
Accepted: April 05, 2022
Published online: May 24, 2022

Number of Print Pages: 11
Number of Figures: 6
Number of Tables: 0

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.